par Reid, Ian R;Brown, Jacques;Burckhardt, Peter;Horowitz, Zebulun;Richardson, Peter;Trechsel, Ulrich;Widmer, Albert;Devogelaer, Jean-Pierre;Kaufman, Jean-Marc;Jaeger, Philippe;Body, Jean-Jacques 
;Brandi, Maria Luisa;Broell, Johann;Di Micco, Raffaele;Genazzani, Andrea Riccardo;Felsenberg, Dieter;Happ, Joachim;Hooper, Michael;Ittner, Jochen;Leb, Georg;Mallmin, Hans;Murray, Timothy;Ortolani, Sergio;Rubinacci, Alessandro;Saaf, Maria;Samsioe, Göran;Verbruggen, Leon A;Meunier, Pierre J.
Référence The New England journal of medicine, 346, 9, page (653-661)
Publication Publié, 2002-02
;Brandi, Maria Luisa;Broell, Johann;Di Micco, Raffaele;Genazzani, Andrea Riccardo;Felsenberg, Dieter;Happ, Joachim;Hooper, Michael;Ittner, Jochen;Leb, Georg;Mallmin, Hans;Murray, Timothy;Ortolani, Sergio;Rubinacci, Alessandro;Saaf, Maria;Samsioe, Göran;Verbruggen, Leon A;Meunier, Pierre J.Référence The New England journal of medicine, 346, 9, page (653-661)
Publication Publié, 2002-02
Article révisé par les pairs
| Résumé : | Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored. |
